Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Receptos Continues To Hit Its Marks

Receptos (RCPT) has given its shareholders a pretty wild ride, even for an early-stage biotech. Up around 125% from when I wrote on it as a Top Idea and 39% from my Christmas Eve update, the intervening time has seen the shares shoot up to $55 (90% higher than the price on Christmas Eve) on expectations for strong Phase II data and rumors of a buyout before the shares were cut in half over two months as that speculation cooled and momentum investors bailed out of biotechs.

Now the roller coaster is shooting higher again as those strong Phase II data on RPC1063 in relapsing multiple sclerosis have materialized. Receptos still has to successfully complete its Phase III study,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details